がんバイオマーカー市場規模、シェア、動向、2032年までの世界予測

がんバイオマーカー市場は、2026年には約282億5000万米ドルと評価され、2032年には544億8000万米ドルに成長し、成長率は11.6%に達するとMarketsandMarketsでは予測しています。

市場は着実に成長しており、病院や診断検査機関は、患者の予後改善のために、疾患の早期発見と正確な診断に注力しています。急速な技術進歩や世界的ながん罹患率の上昇といった要因が、がんバイオマーカー開発における市場拡大を後押ししています。しかし、この市場の拡大を阻む主な障害は、がんバイオマーカーの検証の難しさと、資格のある人材の不足です。

調査範囲：

本調査レポートは、がんバイオマーカー市場を、技術（オミクス技術、イメージング技術）、がんの種類（乳がん、肺がん、大腸がん、前立腺がん、悪性黒色腫、白血病、甲状腺がん、膀胱がん、非ホジキンリンパ腫（NHL）、腎臓がん、その他のがん）、製品の種類（消耗品、機器、バイオインフォマティクスソフトウェア）、用途（診断、研究開発、予後予測、リスク評価）、エンドユーザー（診断検査機関、バイオ医薬品企業およびCRO、研究機関および学術機関）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ、GCC諸国）別に分類しています。レポートの範囲は、がんバイオマーカー市場の成長に影響を与える主要な要因（推進要因、阻害要因、機会、課題など）に関する詳細な情報を含んでいます。主要な業界プレーヤーの詳細な分析を実施し、事業概要、ソリューション、パートナーシップ、コラボレーション、事業拡大、契約、新製品発売などの主要戦略、およびがんバイオマーカー市場における最近の動向に関する洞察を提供します。本レポートは、がんバイオマーカー市場のエコシステムにおける新興スタートアップ企業の競合分析も網羅しています。

本レポートを購入する理由：

本レポートは、がんバイオマーカー市場全体およびサブセグメントの収益に関する最も正確な推定値を提供することで、市場リーダーおよび新規参入企業を支援します。関係者は、競争環境を理解し、より深い洞察を得て、事業をより適切に位置づけ、適切な市場参入戦略を策定することができます。また、本レポートは、関係者が市場の動向を把握し、主要な市場推進要因、阻害要因、機会、および課題に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

がんバイオマーカー市場の成長に影響を与える主要な推進要因（がんバイオマーカーの技術進歩、がん罹患率の増加、創薬・開発におけるがんバイオマーカーの採用拡大、バイオマーカー革新のための研究開発投資の増加、非侵襲的診断法（リキッドバイオプシー）の普及拡大、政府による支援的な取り組みとがん啓発プログラム）、阻害要因（バイオマーカーの商業化に必要な高額な資本と長期にわたる開発期間、不利な規制枠組みと償還制限、バイオマーカーを用いた診断検査の高コスト）、機会（個別化医療と精密医療の役割拡大、腫瘍学におけるコンパニオン診断の応用拡大、新興国における成長可能性、バイオマーカーの発見と分析におけるAIとマルチオミクスアプローチの統合）、および課題（サンプル採取、取り扱い、保管に関する技術的課題、バイオマーカーの検証と標準化に伴う複雑性、熟練した専門家と技術的専門知識の不足）の分析。

• 製品開発／イノベーション：がんバイオマーカー市場における最新技術、研究開発活動、製品発売に関する詳細な分析
• 市場開発：有望な市場に関する包括的な情報 ― 本レポートは、様々な地域におけるがんバイオマーカー市場を分析します
• 市場の多様化：がんバイオマーカー市場における新製品、未開拓地域、最新動向、投資に関する詳細な情報
• 競合分析：ロシュ（スイス）、サーモフィッシャー（米国）、イルミナ（米国）、アジレント・テクノロジー（米国）、キアゲン（オランダ）といった主要企業の市場シェア、成長戦略、製品ラインナップに関する詳細な分析

Report Description

The market for cancer biomarkers is valued at around USD 28.25 billion in 2026 and is forecast to reach USD 54.48 billion by 2032, representing a growth of 11.6%. The market is growing steadily, and hospitals and diagnostic laboratories are focusing on the early detection and accurate diagnosis of diseases to improve patient outcomes. Factors such as rapid technological advances and the global rise in cancer incidence propel market expansion in the development of cancer biomarkers. However, the main obstacles to this market’s expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.

“The omics technology segment is predicted to showcase the highest CAGR during the forecast period.”

The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2025. This is explained by the growing use of proteomics and genomics in drug discovery and development, as well as by improved cancer diagnostics.

“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period.”

The market for cancer biomarkers is divided into categories according to the type of cancer, including non-Hodgkin’s lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In the market for cancer biomarkers in 2025, the breast cancer category had the fastest growth rate. Advances in technology, the rising global prevalence of cancer, and the development of cancer biomarkers are two important factors driving this segment’s growth.

“The diagnostic laboratories segment accounted for the highest share.”

Based on end user, the cancer biomarkers market is segmented into diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes, and other end-users. In 2025, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. The growing number of clinical laboratories worldwide performing cancer biomarker-based diagnostic tests and the rising prevalence of malignancies are responsible for this end-user segment’s sizable share.

“Asia Pacific is expected to register the fastest growth rate in the cancer biomarkers market, by region.”

The region is witnessing a growth spurt due to several key factors, including expanded healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cancer cases and technological advancements in cancer biomarker development are driving growth in the cancer biomarker market in the Asia Pacific region.

The break-up of profiles of primary participants in the cancer biomarkers market:

• By Company Type: Tier 1 – 26%, Tier 2 – 44%, and Tier – 30%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America –5 %, Middle East & Africa- 4%, GCC Countries- 1%

The key players in the cancer biomarkers market are Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), QIAGEN (Netherlands), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), and Merck Millipore (US).

Research Coverage:

This research report categorizes the cancer biomarkers market by profiling technology (omics technologies, imaging technologies), cancer type (breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkin’s lymphoma (NHL), kidney, and other cancers), product type (consumables, instruments, and bioinformatics software), application (diagnostics, research & development, prognostics, risk assessment), end user (diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the cancer biomarkers market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the cancer biomarkers market. This report covers a competitive analysis of upcoming startups in the cancer biomarker market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarkers market and the subsegments. It will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Technological advancements in cancer biomarkers, increasing incidence of cancer, growing adoption of cancer biomarkers in drug discovery and development, increasing investments in research and development for biomarker innovation, growing adoption of non-invasive diagnostics (liquid biopsy), supportive government initiatives and cancer awareness programs), restraints (High capital requirements and long development timelines for biomarker commercialization, unfavorable regulatory frameworks and reimbursement limitations, high cost of biomarker-based diagnostic tests), opportunities (Expanding role of personalized and precision medicine, increasing applications of companion diagnostics in oncology, growth potential in emerging economies, integration of AI and multi-omics approaches in biomarker discovery and analysis), and challenges (Technical challenges related to sample collection, handling, and storage, complexities associated with biomarker validation and standardization, shortage of skilled professionals and technical expertise) influencing the growth of the cancer biomarkers market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the cancer biomarkers market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the cancer biomarker market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarkers market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), and QIAGEN (Netherlands)

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 41
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 41
1.3.2 INCLUSIONS AND EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 43
1.4 CURRENCY CONSIDERED 43
1.5 STAKEHOLDERS 43
1.6 SUMMARY OF CHANGES 44
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET 47
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 CANCER BIOMARKERS MARKET OVERVIEW 50
3.2 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 51
3.3 CANCER BIOMARKERS MARKET, BY CANCER TYPE 51
3.4 CANCER BIOMARKERS MARKET, BY PRODUCT 52
3.5 CANCER BIOMARKERS MARKET, BY APPLICATION 52
3.6 CANCER BIOMARKERS MARKET, BY END USER 53
3.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4 MARKET OVERVIEW 54
4.1 INTRODUCTION 54
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 55
4.2.1.1 Technological Advancements in Cancer Biomarkers 55
4.2.1.2 Increasing incidence of cancer 56
4.2.1.3 Growing adoption of cancer biomarkers in drug discovery and development 58
4.2.1.4 Increasing investments in research and development for biomarker innovation 59
4.2.1.5 Growing Adoption of Non-Invasive Diagnostics (Liquid Biopsy) 59
4.2.1.6 Supportive Government Initiatives and Cancer Awareness Programs 60
4.2.2 RESTRAINTS 61
4.2.2.1 High capital requirements and long development timelines for biomarker commercialization 61
4.2.2.2 Unfavorable regulatory frameworks and reimbursement limitations 62
4.2.2.3 High Cost of Biomarker-Based Diagnostic Tests 62
4.2.3 OPPORTUNITIES 63
4.2.3.1 Expanding role of personalized and precision medicine 63
4.2.3.2 Increasing applications of companion diagnostics in oncology 63
4.2.3.3 Growth potential in emerging economies 64
4.2.3.4 Integration of AI and Multi-Omics Approaches in Biomarker Discovery and Analysis 65
4.2.4 CHALLENGES 65
4.2.4.1 Technical challenges related to sample collection, handling, and storage 65
4.2.4.2 Complexities associated with biomarker validation and standardization 66
4.2.4.3 Shortage of skilled professionals and technical expertise 67
4.3 UNMET NEEDS AND WHITE SPACES 67
4.3.1 UNMET NEEDS IN CANCER BIOMARKERS MARKET 67
4.3.2 WHITE SPACE OPPORTUNITIES 68
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 69
4.4.1 INTERCONNECTED MARKETS 69
4.4.2 CROSS-SECTOR OPPORTUNITIES 70
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 71
4.5.1 KEY MOVES AND STRATEGIC FOCUS 71
5 INDUSTRY TRENDS 72
5.1 PORTER’S FIVE FORCES ANALYSIS 72
5.1.1 THREAT OF NEW ENTRANTS 73
5.1.2 THREAT OF SUBSTITUTES 73
5.1.3 BARGAINING POWER OF BUYERS 73
5.1.4 BARGAINING POWER OF SUPPLIERS 73
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.2 MACROECONOMIC INDICATORS 74
5.2.1 SINTRODUCTION 74
5.2.2 GDP TRENDS AND FORECAST 74
5.3 SUPPLY CHAIN ANALYSIS 77
5.4 VALUE CHAIN ANALYSIS 78
5.5 ECOSYSTEM ANALYSIS 80
5.6 PRICING ANALYSIS 81
5.6.1 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER,
2024–2026 81
5.6.2 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 82
5.7 TRADE ANALYSIS 83
5.7.1 IMPORT SCENARIO (HS CODE 382200) 83
5.7.2 EXPORT SCENARIO (HS CODE 382200) 83
5.8 KEY CONFERENCES & EVENTS, 2026–2027 84
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 85
5.10 INVESTMENT & FUNDING SCENARIO 86
5.11 IMPACT OF 2025 US TARIFF ON CANCER BIOMARKERS MARKET 86
5.11.1 INTRODUCTION 86
5.11.2 KEY TARIFF RATES 87
5.11.3 PRICE IMPACT ANALYSIS 87
5.11.4 IMPACT ON REGION 88
5.11.4.1 North America 88
5.11.4.2 Europe 88
5.11.4.3 Asia Pacific 88
5.11.5 IMPACT ON END-USE INDUSTRIES 89
5.11.5.1 Diagnostic Laboratories 89
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 90
6.1 KEY EMERGING TECHNOLOGIES 90
6.1.1 NEXT-GENERATION SEQUENCING 90
6.1.2 POLYMERASE CHAIN REACTION 90
6.1.3 IMMUNOASSAYS 91
6.2 COMPLEMENTARY TECHNOLOGIES 91
6.2.1 BIOINFORMATICS PLATFORMS 91
6.2.2 MASS SPECTROMETRY 92
6.3 ADJACENT TECHNOLOGIES 92
6.3.1 LIQUID BIOPSY TECHNOLOGIES 92
6.3.2 MICROARRAY TECHNOLOGIES 93
6.4 TECHNOLOGY/PRODUCT ROADMAP 93
6.5 PATENT ANALYSIS 95
6.5.1 LIST OF KEY PATENTS 96
6.6 FUTURE APPLICATIONS 97
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER BIOMARKERS MARKET 97
6.7.1 INTRODUCTION 97
6.7.2 TOP USE CASES AND MARKET POTENTIAL 98
6.7.3 KEY COMPANIES IMPLEMENTING AI 99
6.7.4 FUTURE OF AI 99

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
7.1 DECISION-MAKING PROCESS 100
7.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 100
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
7.2.2 BUYING CRITERIA 101
7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
7.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 103
7.5 MARKET PROFITABILITY 104
7.5.1 REVENUE POTENTIAL 104
7.5.2 COST DYNAMICS 105
7.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105
8 CANCER BIOMARKERS MARKET, BY TECHNOLOGY 106
8.1 INTRODUCTION 107
8.2 OMICS TECHNOLOGIES 107
8.2.1 PROTEOMICS 110
8.2.1.1 Immunoassays 114
8.2.1.1.1 Facilitate diagnosis of cancer at early stage 114
8.2.1.2 Mass spectrometry 115
8.2.1.2.1 High specificity of mass spectroscopy to drive adoption 115
8.2.1.3 2D gel electrophoresis 116
8.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment 116
8.2.1.4 Protein microarrays 117
8.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth 117
8.2.1.5 Other proteomic technologies 118
8.2.2 GENOMICS 120
8.2.2.1 Next-generation sequencing 123
8.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth 123
8.2.2.2 Polymerase chain reaction 124
8.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market 124
8.2.2.3 In situ hybridization 125
8.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials 125
8.2.3 OTHER OMICS TECHNOLOGIES 126
8.3 IMAGING TECHNOLOGIES 129
8.3.1 ULTRASOUND IMAGING 132
8.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth 132

8.3.2 COMPUTED TOMOGRAPHY 135
8.3.2.1 Technological advancements to drive adoption 135
8.3.3 MAGNETIC RESONANCE IMAGING 138
8.3.3.1 Growing preference for open MRIs to support market growth 138
8.3.4 POSITRON EMISSION TOMOGRAPHY 141
8.3.4.1 Development of lab-on-chip-based multiplex assays to propel market 141
8.3.5 MAMMOGRAPHY 144
8.3.5.1 Advanced technologies like 3D mammography to support market growth 144
9 CANCER BIOMARKERS MARKET, BY CANCER TYPE 148
9.1 INTRODUCTION 149
9.2 BREAST CANCER 150
9.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET 150
9.3 LUNG CANCER 153
9.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH 153
9.4 COLORECTAL CANCER 156
9.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET 156
9.5 PROSTATE CANCER 159
9.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET 159
9.6 MELANOMA 162
9.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET 162
9.7 LEUKEMIA 165
9.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET 165
9.8 THYROID CANCER 168
9.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH 168
9.9 BLADDER CANCER 171
9.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET 171
9.10 NON-HODGKIN’S LYMPHOMA 174
9.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET 174
9.11 KIDNEY CANCER 177
9.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET 177
9.12 OTHER CANCERS 180

10 CANCER BIOMARKERS MARKET, BY PRODUCT 184
10.1 INTRODUCTION 185
10.2 CONSUMABLES 185
10.2.1 KITS & REAGENTS 188
10.2.1.1 Ease of use to support adoption 188
10.2.2 ANTIBODIES 191
10.2.2.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market 191
10.2.3 PROBES 194
10.2.3.1 Need for probes in assay tests for cancer detection to support market growth 194
10.3 INSTRUMENTS 197
10.3.1 IMAGING INSTRUMENTS 200
10.3.1.1 Technological advancements in imaging instruments to drive growth 200
10.3.2 PATHOLOGY-BASED INSTRUMENTS 202
10.3.2.1 Rising demand for cancer diagnosis to drive market 202
10.3.3 BIOPSY INSTRUMENTS 205
10.3.3.1 Increasing prevalence of cancer to drive growth 205
10.4 BIOINFORMATICS SOFTWARE 207
10.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET 207
11 CANCER BIOMARKERS MARKET, BY APPLICATION 211
11.1 INTRODUCTION 212
11.2 DIAGNOSTICS 212
11.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET 212
11.3 RESEARCH & DEVELOPMENT 215
11.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 215
11.4 PROGNOSTICS 218
11.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH 218
11.5 RISK ASSESSMENT 221
11.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS 221
11.6 OTHER APPLICATIONS 224
12 CANCER BIOMARKERS MARKET, BY END USER 228
12.1 INTRODUCTION 229
12.2 DIAGNOSTIC LABORATORIES 229
12.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH 229

12.3 BIOPHARMACEUTICAL COMPANIES AND CROS 232
12.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 232
12.4 RESEARCH AND ACADEMIC INSTITUTES 235
12.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET 235
12.5 OTHER END USERS 239
13 CANCER BIOMARKERS MARKET, BY REGION 242
13.1 INTRODUCTION 243
13.2 NORTH AMERICA 244
13.2.1 US 251
13.2.1.1 High adoption of precision oncology and biomarker-driven therapies to drive market growth 251
13.2.2 CANADA 257
13.2.2.1 Government Initiatives Driving Biomarker Growth 257
13.3 EUROPE 264
13.3.1 GERMANY 272
13.3.1.1 High Healthcare Spending Driving Biomarker Adoption 272
13.3.2 UK 278
13.3.2.1 Rising Cancer Incidence Driving Biomarker Adoption 278
13.3.3 FRANCE 283
13.3.3.1 Government Funding Supporting Biomarker Market Growth 283
13.3.4 ITALY 288
13.3.4.1 Growing geriatric population to support market growth 288
13.3.5 SPAIN 293
13.3.5.1 Rising emphasis on personalized medicine to drive market growth 293
13.3.6 REST OF EUROPE 298
13.4 ASIA PACIFIC 304
13.4.1 CHINA 311
13.4.1.1 Rising cancer burden and strong government support to drive market growth 311
13.4.2 JAPAN 316
13.4.2.1 Strong healthcare investment to drive market growth 316
13.4.3 INDIA 321
13.4.3.1 Rising cancer burden and expanding healthcare investments to drive market growth 321
13.4.4 AUSTRALIA 326
13.4.4.1 Rising cancer burden and strong government investments to drive market growth 326
13.4.5 REST OF ASIA PACIFIC 331

13.5 LATIN AMERICA 337
13.5.1 BRAZIL 342
13.5.1.1 Rising cancer incidence to drive market growth 342
13.5.2 MEXICO 347
13.5.2.1 Expanding healthcare access and rising cancer burden to drive market growth 347
13.5.3 REST OF LATIN AMERICA 352
13.6 MIDDLE EAST & AFRICA 358
13.6.1 EMERGING PRECISION MEDICINE INITIATIVES TO DRIVE MARKET GROWTH 358
13.7 GCC COUNTRIES 363
13.7.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH 363
14 COMPETITIVE LANDSCAPE 369
14.1 INTRODUCTION 369
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 369
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER BIOMARKERS MARKET 369
14.3 REVENUE ANALYSIS, 2023–2025 371
14.4 MARKET SHARE ANALYSIS, 2025 372
14.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 372
14.4.2 US: MARKET SHARE ANALYSIS, 2025 374
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 374
14.5.1 STARS 374
14.5.2 EMERGING LEADERS 375
14.5.3 PERVASIVE PLAYERS 375
14.5.4 PARTICIPANTS 375
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 377
14.5.5.1 Company footprint 377
14.5.5.2 Regional footprint 377
14.5.5.3 Product footprint 378
14.5.5.4 Profiling Technology footprint 379
14.5.5.5 Application footprint 379
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 380
14.6.1 PROGRESSIVE COMPANIES 380
14.6.2 RESPONSIVE COMPANIES 380
14.6.3 DYNAMIC COMPANIES 380
14.6.4 STARTING BLOCKS 380
14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 382
14.6.5.1 Detailed list of key startups/SMEs 382
14.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 382
14.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 383

14.7 COMPANY VALUATION & FINANCIAL METRICS 383
14.7.1 FINANCIAL METRICS 383
14.7.2 COMPANY VALUATION 384
14.8 BRAND/PRODUCT COMPARISON 384
14.9 COMPETITIVE SCENARIO 385
14.9.1 PRODUCT LAUNCHES & APPROVALS 385
14.9.2 DEALS 386
15 COMPANY PROFILES 387
15.1 KEY PLAYERS 387
15.1.1 F. HOFFMANN-LA ROCHE AG 387
15.1.1.1 Business overview 387
15.1.1.2 Products offered 388
15.1.1.3 Recent developments 390
15.1.1.3.1 Product launches & approvals 390
15.1.1.3.2 Deals 391
15.1.1.4 MnM view 391
15.1.1.4.1 Key strengths 391
15.1.1.4.2 Strategic choices 391
15.1.1.4.3 Weaknesses and competitive threats 392
15.1.2 THERMO FISHER SCIENTIFIC 393
15.1.2.1 Business overview 393
15.1.2.2 Products offered 394
15.1.2.3 Recent developments 397
15.1.2.3.1 Product launches & approvals 397
15.1.2.3.2 Deals 397
15.1.2.4 MnM view 397
15.1.2.4.1 Key strengths 397
15.1.2.4.2 Strategic choices 398
15.1.2.4.3 Weaknesses & competitive threats 398
15.1.3 ILLUMINA, INC. 399
15.1.3.1 Business overview 399
15.1.3.2 Products & services offered 400
15.1.3.3 Recent developments 402
15.1.3.3.1 Product launches & approvals 402
15.1.3.3.2 Deals 402
15.1.3.4 MnM view 403
15.1.3.4.1 Key strengths 403
15.1.3.4.2 Strategic choices 403
15.1.3.4.3 Weaknesses and competitive threats 403

15.1.4 AGILENT TECHNOLOGIES, INC. 404
15.1.4.1 Business overview 404
15.1.4.2 Products & services offered 405
15.1.4.3 Recent developments 407
15.1.4.3.1 Product launches & approvals 407
15.1.4.3.2 Deals 408
15.1.4.4 MnM view 408
15.1.4.4.1 Key strengths 408
15.1.4.4.2 Strategic choices 408
15.1.4.4.3 Weaknesses and competitive threats 409
15.1.5 QIAGEN 410
15.1.5.1 Business overview 410
15.1.5.2 Products & services offered 411
15.1.5.3 Recent developments 412
15.1.5.3.1 Product launches & approvals 412
15.1.5.3.2 Deals 413
15.1.5.4 MnM view 413
15.1.5.4.1 Key strengths 413
15.1.5.4.2 Strategic choices 413
15.1.5.4.3 Weaknesses & competitive threats 414
15.1.6 BIO-RAD LABORATORIES, INC. 415
15.1.6.1 Business overview 415
15.1.6.2 Products & services offered 416
15.1.6.3 Recent developments 417
15.1.6.3.1 Deals 417
15.1.7 DANAHER CORPORATION 418
15.1.7.1 Business overview 418
15.1.7.2 Products offered 419
15.1.8 ABBOTT LABORATORIES 421
15.1.8.1 Business overview 421
15.1.8.2 Products offered 422
15.1.8.3 Recent developments 423
15.1.8.3.1 Deals 423
15.1.9 BIOMÉRIEUX 424
15.1.9.1 Business overview 424
15.1.9.2 Products & services offered 425
15.1.10 MERCK KGAA 426
15.1.10.1 Business overview 426
15.1.10.2 Products & services offered 427
15.1.10.3 Recent developments 428
15.1.10.3.1 Product launches & approvals 428

15.1.11 SIEMENS HEALTHINEERS AG 429
15.1.11.1 Business overview 429
15.1.11.2 Products offered 430
15.1.12 BECTON, DICKINSON AND COMPANY 432
15.1.12.1 Business overview 432
15.1.12.2 Products offered 433
15.2 OTHER PLAYERS 435
15.2.1 MYRIAD GENETICS 435
15.2.2 SYSMEX CORPORATION 436
15.2.3 HOLOGIC, INC. 437
15.2.4 QUEST DIAGNOSTICS 438
15.2.5 CENTOGENE N.V. 439
15.2.6 BIOGENEX 440
15.2.7 R&D SYSTEMS, INC. 441
15.2.8 BIOVISION INC. 442
15.2.9 OLINK 443
15.2.10 ASURAGEN, INC. 444
15.2.11 MESO SCALE DIAGNOSTICS, LLC 445
15.2.12 INVIVOSCRIBE, INC. 446
15.2.13 INOVIQ LTD. 447
15.2.14 NANTOMICS 448
16 RESEARCH METHODOLOGY 449
16.1 RESEARCH DATA 449
16.1.1 SECONDARY DATA 450
16.1.1.1 List of secondary sources 450
16.1.1.2 Key data from secondary sources 451
16.1.2 PRIMARY DATA 451
16.1.2.1 List of primary sources 452
16.1.2.2 Key data from primary sources 452
16.1.2.3 Key industry insights 453
16.1.2.4 Breakdown of primary interviews 454
16.2 MARKET SIZE ESTIMATION 454
16.2.1 TOTAL MARKET SIZE: CANCER BIOMARKERS MARKET 454
16.2.2 BOTTOM-UP APPROACH 454
16.2.2.1 Approach 1: Revenue estimation of key players 455
16.2.2.2 Approach 2: Study of annual reports and investor presentations 455
16.2.2.3 Approach 3: Primary interviews 455
16.2.2.4 Growth forecast 456
16.2.2.5 CAGR projections 456
16.2.3 TOP-DOWN APPROACH 457

16.3 DATA TRIANGULATION 458
16.4 RESEARCH ASSUMPTIONS 458
16.4.1 STUDY-RELATED ASSUMPTIONS 458
16.5 STUDY ASSUMPTIONS 459
16.5.1 PARAMETRIC ASSUMPTIONS 459
16.5.2 GROWTH RATE ASSUMPTIONS 460
16.6 RESEARCH LIMITATIONS 460
16.7 RISK ASSESSMENT 460
17 APPENDIX 461
17.1 DISCUSSION GUIDE 461
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 464
17.3 CUSTOMIZATION OPTIONS 466
17.4 RELATED REPORTS 466
17.5 AUTHOR DETAILS 467

LIST OF TABLES

TABLE 1 INCLUSIONS AND EXCLUSIONS 42
TABLE 2 ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE,
BOTH SEXES, AGE [0-85+] ALL CANCERS 57
TABLE 3 CANCER INCIDENCE, BOTH SEXES, IN 2022 57
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS 61
TABLE 5 IMPACT OF PORTER’S FIVE FORCES ON CANCER BIOMARKERS MARKET 73
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 74
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS 75
TABLE 8 EUROPE: MACROECONOMIC INDICATORS 76
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS 76
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS 76
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 76
TABLE 12 CANCER BIOMARKERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 81
TABLE 13 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER,
2024–2026 (USD) 82
TABLE 14 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 (USD) 82
TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83
TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 83
TABLE 17 CANCER BIOMARKERS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 84
TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES 87
TABLE 19 KEY PATENTS IN CANCER BIOMARKERS MARKET, 2022–2026 96
TABLE 20 KEY COMPANIES IMPLEMENTING AI IN CANCER BIOMARKERS MARKET 99
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 101
TABLE 22 KEY BUYING CRITERIA, BY PRODUCT 101
TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
TABLE 24 CANCER BIOMARKERS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 103
TABLE 25 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 107
TABLE 26 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE,
2024–2032 (USD MILLION) 108
TABLE 27 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION,
2024–2032 (USD MILLION) 108
TABLE 28 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 109
TABLE 29 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 109
TABLE 30 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 110
TABLE 31 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 110
TABLE 32 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 111
TABLE 33 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2024–2032 (USD MILLION) 112
TABLE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS,
BY COUNTRY, 2024–2032 (USD MILLION) 112
TABLE 35 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 113
TABLE 36 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 113
TABLE 37 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 114
TABLE 38 IMMUNOASSAYS MARKET, BY REGION, 2024–2032 (USD MILLION) 115
TABLE 39 MASS SPECTROMETRY MARKET, BY REGION, 2024–2032 (USD MILLION) 116
TABLE 40 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2024–2032 (USD MILLION) 117
TABLE 41 PROTEIN MICROARRAYS MARKET, BY REGION, 2024–2032 (USD MILLION) 118
TABLE 42 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION,
2024–2032 (USD MILLION) 120
TABLE 43 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 121
TABLE 44 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2024–2032 (USD MILLION) 121
TABLE 45 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION) 122
TABLE 46 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2024–2032 (USD MILLION) 122
TABLE 47 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 123
TABLE 48 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 123
TABLE 49 NEXT-GENERATION SEQUENCING MARKET, BY REGION,
2024–2032 (USD MILLION) 124
TABLE 50 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2024–2032 (USD MILLION) 125
TABLE 51 IN SITU HYBRIDIZATION MARKET, BY REGION, 2024–2032 (USD MILLION) 126
TABLE 52 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION) 127
TABLE 53 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 127
TABLE 54 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 128
TABLE 55 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 128
TABLE 56 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 129
TABLE 57 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE,
2024–2032 (USD MILLION) 130
TABLE 58 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION,
2024–2032 (USD MILLION) 130
TABLE 59 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 131
TABLE 60 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 131
TABLE 61 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY COUNTRY, 2024–2032 (USD MILLION) 132
TABLE 62 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 132
TABLE 63 ULTRASOUND IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION) 133
TABLE 64 NORTH AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 133
TABLE 65 EUROPE: ULTRASOUND IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 134
TABLE 66 ASIA PACIFIC: ULTRASOUND IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 134
TABLE 67 LATIN AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 135
TABLE 68 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION) 136
TABLE 69 NORTH AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 136
TABLE 70 EUROPE: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 137
TABLE 71 ASIA PACIFIC: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 137
TABLE 72 LATIN AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 138
TABLE 73 MAGNETIC RESONANCE IMAGING MARKET, BY REGION,
2024–2032 (USD MILLION) 139
TABLE 74 NORTH AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 139
TABLE 75 EUROPE: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 140
TABLE 76 ASIA PACIFIC: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 140
TABLE 77 LATIN AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 141
TABLE 78 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION,
2024–2032 (USD MILLION) 142
TABLE 79 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 142
TABLE 80 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 143
TABLE 81 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 143
TABLE 82 LATIN AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 144
TABLE 83 MAMMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION) 145
TABLE 84 NORTH AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 145
TABLE 85 EUROPE: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 146
TABLE 86 ASIA PACIFIC: MAMMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 146
TABLE 87 LATIN AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 147
TABLE 88 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 149
TABLE 89 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 151
TABLE 90 BREAST CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 151
TABLE 91 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 151
TABLE 92 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 152
TABLE 93 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 152
TABLE 94 LATIN AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 153
TABLE 95 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 154
TABLE 96 LUNG CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 154
TABLE 97 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 155
TABLE 98 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 155
TABLE 99 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 156
TABLE 100 LATIN AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 156
TABLE 101 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION,
2022 VS. 2040 157
TABLE 102 COLORECTAL CANCER BIOMARKERS MARKET, BY REGION,
2024–2032 (USD MILLION) 157
TABLE 103 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 158
TABLE 104 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 158
TABLE 105 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 159
TABLE 106 LATIN AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 159
TABLE 107 PROSTATE CANCER BIOMARKERS MARKET, BY REGION,
2024–2032 (USD MILLION) 160
TABLE 108 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 161
TABLE 109 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 161
TABLE 110 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 162
TABLE 111 LATIN AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 162
TABLE 112 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040 163
TABLE 113 MELANOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 163
TABLE 114 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 164
TABLE 115 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 164
TABLE 116 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 165
TABLE 117 LATIN AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 165
TABLE 118 LEUKEMIA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 166
TABLE 119 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 166
TABLE 120 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 167
TABLE 121 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 167
TABLE 122 LATIN AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 168
TABLE 123 THYROID CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 169
TABLE 124 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 169
TABLE 125 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 170
TABLE 126 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 170
TABLE 127 LATIN AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 171
TABLE 128 BLADDER CANCER BIOMARKERS MARKET, BY REGION,
2024–2032 (USD MILLION) 172
TABLE 129 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 172
TABLE 130 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 173
TABLE 131 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 173
TABLE 132 LATIN AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 174
TABLE 133 NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION,
2024–2032 (USD MILLION) 175
TABLE 134 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 175
TABLE 135 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 176
TABLE 136 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 176
TABLE 137 LATIN AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET,
BY COUNTRY, 2024–2032 (USD MILLION) 177
TABLE 138 KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 178
TABLE 139 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 178
TABLE 140 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 179
TABLE 141 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 179
TABLE 142 LATIN AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 180
TABLE 143 OTHER CANCERS BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 181
TABLE 144 NORTH AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 181
TABLE 145 EUROPE: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 182
TABLE 146 ASIA PACIFIC: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 182
TABLE 147 LATIN AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 183
TABLE 148 CANCER BIOMARKERS MARKET, BY PRODUCTS, 2024–2032 (USD MILLION) 185
TABLE 149 CANCER BIOMARKERS CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 186
TABLE 150 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION,
2024–2032 (USD MILLION) 186
TABLE 151 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 187
TABLE 152 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 187
TABLE 153 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 188
TABLE 154 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 188
TABLE 155 KITS & REAGENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 189
TABLE 156 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 189
TABLE 157 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 190
TABLE 158 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 190
TABLE 159 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 191
TABLE 160 ANTIBODIES MARKET, BY REGION, 2024–2032 (USD MILLION) 192
TABLE 161 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 192
TABLE 162 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 193
TABLE 163 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 193
TABLE 164 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 194
TABLE 165 PROBES MARKET, BY REGION, 2024–2032 (USD MILLION) 194
TABLE 166 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 195
TABLE 167 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 195
TABLE 168 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 196
TABLE 169 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 196
TABLE 170 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 197
TABLE 171 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION,
2024–2032 (USD MILLION) 197
TABLE 172 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 198
TABLE 173 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 198
TABLE 174 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 199
TABLE 175 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 199
TABLE 176 IMAGING INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 200
TABLE 177 NORTH AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 201
TABLE 178 EUROPE: IMAGING INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 201
TABLE 179 ASIA PACIFIC: IMAGING INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 202
TABLE 180 LATIN AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 202
TABLE 181 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION,
2024–2032 (USD MILLION) 203
TABLE 182 NORTH AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 203
TABLE 183 EUROPE: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 204
TABLE 184 ASIA PACIFIC: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 204
TABLE 185 LATIN AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 205
TABLE 186 BIOPSY INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 205
TABLE 187 NORTH AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 206
TABLE 188 EUROPE: BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 206
TABLE 189 ASIA PACIFIC: BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 207
TABLE 190 LATIN AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 207
TABLE 191 BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2024–2032 (USD MILLION) 208
TABLE 192 NORTH AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 209
TABLE 193 EUROPE: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 209
TABLE 194 ASIA PACIFIC: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 210
TABLE 195 LATIN AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 210
TABLE 196 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212
TABLE 197 CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY REGION,
2024–2032 (USD MILLION) 213
TABLE 198 NORTH AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 213
TABLE 199 EUROPE: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY,
2024–2032 (USD MILLION) 214
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 214
TABLE 201 LATIN AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 215
TABLE 202 CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY REGION, 2024–2032 (USD MILLION) 216
TABLE 203 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 216
TABLE 204 EUROPE: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT,
BY COUNTRY, 2024–2032 (USD MILLION) 217
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT,
BY COUNTRY, 2024–2032 (USD MILLION) 217
TABLE 206 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 218
TABLE 207 CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY REGION,
2024–2032 (USD MILLION) 219
TABLE 208 NORTH AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 219
TABLE 209 EUROPE: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY,
2024–2032 (USD MILLION) 220
TABLE 210 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 220
TABLE 211 LATIN AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 221
TABLE 212 CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY REGION,
2024–2032 (USD MILLION) 222
TABLE 213 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT,
BY COUNTRY, 2024–2032 (USD MILLION) 222
TABLE 214 EUROPE: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION) 223
TABLE 215 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT,
BY COUNTRY, 2024–2032 (USD MILLION) 223
TABLE 216 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT,
BY COUNTRY, 2024–2032 (USD MILLION) 224
TABLE 217 CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY REGION,
2024–2032 (USD MILLION) 225
TABLE 218 NORTH AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS,
BY COUNTRY, 2024–2032 (USD MILLION) 225
TABLE 219 EUROPE: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION) 226
TABLE 220 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS,
BY COUNTRY, 2024–2032 (USD MILLION) 226
TABLE 221 LATIN AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS,
BY COUNTRY, 2024–2032 (USD MILLION) 227
TABLE 222 CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 229
TABLE 223 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2032 (USD MILLION) 230
TABLE 224 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 231
TABLE 225 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES,
BY COUNTRY, 2024–2032 (USD MILLION) 231
TABLE 226 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 232
TABLE 227 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 232
TABLE 228 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2024–2032 (USD MILLION) 233
TABLE 229 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 234
TABLE 230 EUROPE: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 234
TABLE 231 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 235
TABLE 232 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 235
TABLE 233 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES,
BY REGION, 2024–2032 (USD MILLION) 236
TABLE 234 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 237
TABLE 235 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 237
TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 238
TABLE 237 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 238
TABLE 238 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION,
2024–2032 (USD MILLION) 239
TABLE 239 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2032 (USD MILLION) 240
TABLE 240 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION) 240
TABLE 241 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2032 (USD MILLION) 241
TABLE 242 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2032 (USD MILLION) 241
TABLE 243 CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 243
TABLE 244 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 244
TABLE 245 NORTH AMERICA: MACROECONOMIC INDICATORS 245
TABLE 246 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 246
TABLE 247 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 246
TABLE 248 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 246
TABLE 249 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 247
TABLE 250 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 247
TABLE 251 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 248
TABLE 252 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 248
TABLE 253 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 249
TABLE 254 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 249
TABLE 255 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 249
TABLE 256 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 250
TABLE 257 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 250
TABLE 258 US – NUMBER OF CANCER BIOMARKER TESTS FOR NON-SMALL CELL LUNG CANCER, BY SAMPLE TYPE, 2024–2032 (TESTS) 252
TABLE 259 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 252
TABLE 260 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE,
2024–2032 (USD MILLION) 253
TABLE 261 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 253
TABLE 262 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 254
TABLE 263 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 254
TABLE 264 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 255
TABLE 265 US: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 255
TABLE 266 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 256
TABLE 267 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 256
TABLE 268 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 256
TABLE 269 US: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 257
TABLE 270 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 258
TABLE 271 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 259
TABLE 272 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 259
TABLE 273 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 260
TABLE 274 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 260
TABLE 275 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 261
TABLE 276 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 261
TABLE 277 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 262
TABLE 278 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 262
TABLE 279 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 263
TABLE 280 CANADA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 263
TABLE 281 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 265
TABLE 282 MACROECONOMIC INDICATORS FOR EUROPE 265
TABLE 283 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 266
TABLE 284 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 266
TABLE 285 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 267
TABLE 286 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 267
TABLE 287 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 268
TABLE 288 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 268
TABLE 289 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 269
TABLE 290 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 269
TABLE 291 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 270
TABLE 292 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 270
TABLE 293 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 271
TABLE 294 EUROPE: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 271
TABLE 295 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 273
TABLE 296 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 273
TABLE 297 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 274
TABLE 298 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 274
TABLE 299 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 275
TABLE 300 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 275
TABLE 301 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 276
TABLE 302 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 276
TABLE 303 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 276
TABLE 304 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 277
TABLE 305 GERMANY: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 277
TABLE 306 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 278
TABLE 307 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE,
2024–2032 (USD MILLION) 279
TABLE 308 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 279
TABLE 309 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 280
TABLE 310 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 280
TABLE 311 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 281
TABLE 312 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 281
TABLE 313 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 282
TABLE 314 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 282
TABLE 315 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 282
TABLE 316 UK: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 283
TABLE 317 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 284
TABLE 318 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 284
TABLE 319 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 284
TABLE 320 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 285
TABLE 321 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 285
TABLE 322 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 286
TABLE 323 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 286
TABLE 324 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 287
TABLE 325 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 287
TABLE 326 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 288
TABLE 327 FRANCE: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 288
TABLE 328 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 289
TABLE 329 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 289
TABLE 330 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 290
TABLE 331 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 290
TABLE 332 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 291
TABLE 333 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 291
TABLE 334 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 292
TABLE 335 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 292
TABLE 336 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 292
TABLE 337 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 293
TABLE 338 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 293
TABLE 339 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 294
TABLE 340 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 294
TABLE 341 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 295
TABLE 342 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 295
TABLE 343 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 296
TABLE 344 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 296
TABLE 345 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 297
TABLE 346 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 297
TABLE 347 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 297
TABLE 348 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 298
TABLE 349 SPAIN: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 298
TABLE 350 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 299
TABLE 351 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 299
TABLE 352 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 300
TABLE 353 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 300
TABLE 354 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 301
TABLE 355 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 301
TABLE 356 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 302
TABLE 357 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 302
TABLE 358 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 302
TABLE 359 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 303
TABLE 360 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 303
TABLE 361 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 305
TABLE 362 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 306
TABLE 363 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 306
TABLE 364 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 306
TABLE 365 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 307
TABLE 366 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 307
TABLE 367 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 308
TABLE 368 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 308
TABLE 369 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 309
TABLE 370 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 309
TABLE 371 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 309
TABLE 372 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 310
TABLE 373 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 310
TABLE 374 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 311
TABLE 375 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 312
TABLE 376 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 312
TABLE 377 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 313
TABLE 378 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 313
TABLE 379 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 314
TABLE 380 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 314
TABLE 381 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 315
TABLE 382 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 315
TABLE 383 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 315
TABLE 384 CHINA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 316
TABLE 385 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 317
TABLE 386 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 317
TABLE 387 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 317
TABLE 388 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 318
TABLE 389 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 318
TABLE 390 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 319
TABLE 391 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 319
TABLE 392 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 320
TABLE 393 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 320
TABLE 394 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 320
TABLE 395 JAPAN: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 321
TABLE 396 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 322
TABLE 397 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 322
TABLE 398 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 323
TABLE 399 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 323
TABLE 400 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 324
TABLE 401 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 324
TABLE 402 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 325
TABLE 403 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 325
TABLE 404 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 325
TABLE 405 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 326
TABLE 406 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 326
TABLE 407 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 327
TABLE 408 AUSTRALIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 327
TABLE 409 AUSTRALIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 328
TABLE 410 AUSTRALIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 328
TABLE 411 AUSTRALIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 329
TABLE 412 AUSTRALIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 329
TABLE 413 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 330
TABLE 414 AUSTRALIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 330
TABLE 415 AUSTRALIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 330
TABLE 416 AUSTRALIA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 331
TABLE 417 AUSTRALIA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 331
TABLE 418 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET,
BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 332
TABLE 419 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 332
TABLE 420 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS,
BY TYPE, 2024–2032 (USD MILLION) 333
TABLE 421 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 333
TABLE 422 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 334
TABLE 423 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 334
TABLE 424 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 335
TABLE 425 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 335
TABLE 426 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 335
TABLE 427 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 336
TABLE 428 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 336
TABLE 429 MACROECONOMIC INDICATORS FOR LATIN AMERICA 337
TABLE 430 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY,
2024–2032 (USD MILLION) 338
TABLE 431 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 338
TABLE 432 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 338
TABLE 433 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 339
TABLE 434 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 339
TABLE 435 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 340
TABLE 436 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 340
TABLE 437 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 341
TABLE 438 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 341
TABLE 439 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 341
TABLE 440 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 342
TABLE 441 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 342
TABLE 442 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 343
TABLE 443 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 343
TABLE 444 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 344
TABLE 445 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 344
TABLE 446 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 345
TABLE 447 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 345
TABLE 448 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 346
TABLE 449 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 346
TABLE 450 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 346
TABLE 451 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 347
TABLE 452 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 347
TABLE 453 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2024–2032 (USD MILLION) 348
TABLE 454 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 348
TABLE 455 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE,
2024–2032 (USD MILLION) 349
TABLE 456 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2024–2032 (USD MILLION) 349
TABLE 457 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 350
TABLE 458 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 350
TABLE 459 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 351
TABLE 460 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 351
TABLE 461 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 351
TABLE 462 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 352
TABLE 463 MEXICO: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 352
TABLE 464 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET,
BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 353
TABLE 465 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 353
TABLE 466 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS,
BY TYPE, 2024–2032 (USD MILLION) 354
TABLE 467 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS,
BY TYPE, 2024–2032 (USD MILLION) 354
TABLE 468 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 355
TABLE 469 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 355
TABLE 470 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 356
TABLE 471 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 356
TABLE 472 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 356
TABLE 473 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 357
TABLE 474 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 357
TABLE 475 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET,
BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 358
TABLE 476 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 359
TABLE 477 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS,
BY TYPE, 2024–2032 (USD MILLION) 359
TABLE 478 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS,
BY TYPE, 2024–2032 (USD MILLION) 360
TABLE 479 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 360
TABLE 480 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 361
TABLE 481 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 361
TABLE 482 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 362
TABLE 483 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 362
TABLE 484 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 362
TABLE 485 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 363
TABLE 486 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 364
TABLE 487 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY TYPE, 2024–2032 (USD MILLION) 364
TABLE 488 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 365
TABLE 489 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 365
TABLE 490 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 366
TABLE 491 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2024–2032 (USD MILLION) 366
TABLE 492 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PRODUCT,
2024–2032 (USD MILLION) 367
TABLE 493 GCC COUNTRIES: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE,
2024–2032 (USD MILLION) 367
TABLE 494 GCC COUNTRIES: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE,
2024–2032 (USD MILLION) 367
TABLE 495 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY APPLICATION,
2024–2032 (USD MILLION) 368
TABLE 496 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY END USER,
2024–2032 (USD MILLION) 368
TABLE 497 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CANCER BIOMARKERS MARKET, JANUARY 2023−APRIL 2026 369
TABLE 498 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION 372
TABLE 499 CANCER BIOMARKER MARKET: REGIONAL FOOTPRINT, 2025 377
TABLE 500 CANCER BIOMARKER MARKET: PRODUCT FOOTPRINT, 2025 378
TABLE 501 CANCER BIOMARKER MARKET: PROFILING TECHNOLOGY FOOTPRINT, 2025 379
TABLE 502 CANCER BIOMARKER MARKET: APPLICATION FOOTPRINT, 2025 379
TABLE 503 CANCER BIOMARKER MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025 382
TABLE 504 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2), 2025 382
TABLE 505 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2), 2025 383
TABLE 506 CANCER BIOMARKER MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 385
TABLE 507 CANCER BIOMARKER MARKET: DEALS, JANUARY 2023–APRIL 2026 386
TABLE 508 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 387
TABLE 509 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED 388
TABLE 510 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES & APPROVALS 390
TABLE 511 F. HOFFMANN-LA ROCHE AG: DEALS 391
TABLE 512 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 393
TABLE 513 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 394
TABLE 514 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS 397
TABLE 515 THERMO FISHER SCIENTIFIC INC.: DEALS 397
TABLE 516 ILLUMINA, INC.: COMPANY OVERVIEW 399
TABLE 517 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 400
TABLE 518 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS 402
TABLE 519 ILLUMINA, INC.: DEALS 402
TABLE 520 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 404
TABLE 521 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 405
TABLE 522 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS 407
TABLE 523 AGILENT TECHNOLOGIES, INC.: DEALS 408
TABLE 524 QIAGEN: COMPANY OVERVIEW 410
TABLE 525 QIAGEN: PRODUCTS & SERVICES OFFERED 411
TABLE 526 QIAGEN: PRODUCT LAUNCHES & APPROVALS 412
TABLE 527 QIAGEN: DEALS 413
TABLE 528 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 415
TABLE 529 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 416
TABLE 530 BIO-RAD LABORATORIES, INC.: DEALS 417
TABLE 531 DANAHER CORPORATION: COMPANY OVERVIEW 418
TABLE 532 DANAHER CORPORATION: PRODUCTS OFFERED 419
TABLE 533 ABBOTT LABORATORIES: COMPANY OVERVIEW 421
TABLE 534 ABBOTT LABORATORIES: PRODUCTS OFFERED 422
TABLE 535 ABBOTT LABORATORIES: DEALS 423
TABLE 536 BIOMÉRIEUX: COMPANY OVERVIEW 424
TABLE 537 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 425
TABLE 538 MERCK KGAA: BUSINESS OVERVIEW 426
TABLE 539 MERCK KGAA: PRODUCTS & SERVICES OFFERED 427
TABLE 540 MERCK KGAA: PRODUCT LAUNCHES & APPROVALS 428
TABLE 541 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 429
TABLE 542 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 430
TABLE 543 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 432
TABLE 544 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 433
TABLE 545 MYRIAD GENETICS: COMPANY OVERVIEW 435
TABLE 546 SYSMEX CORPORATION: COMPANY OVERVIEW 436
TABLE 547 HOLOGIC, INC.: COMPANY OVERVIEW 437
TABLE 548 QUEST DIAGNOSTICS: COMPANY OVERVIEW 438
TABLE 549 CENTOGENE N.V.: COMPANY OVERVIEW 439
TABLE 550 BIOGENEX: COMPANY OVERVIEW 440
TABLE 551 R&D SYSTEMS, INC.: COMPANY OVERVIEW 441
TABLE 552 BIOVISION INC.: COMPANY OVERVIEW 442
TABLE 553 OLINK: COMPANY OVERVIEW 443
TABLE 554 ASURAGEN, INC.: COMPANY OVERVIEW 444
TABLE 555 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW 445
TABLE 556 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 446
TABLE 557 INOVIQ LTD.: COMPANY OVERVIEW 447
TABLE 558 NANTOMICS: COMPANY OVERVIEW 448
TABLE 559 KEY DATA FROM PRIMARY SOURCES 452
TABLE 560 CANCER BIOMARKERS MARKET: RISK ASSESSMENT 460

LIST OF FIGURES

FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION 41
FIGURE 2 STUDY YEARS CONSIDERED 43
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
FIGURE 4 GLOBAL CANCER BIOMARKERS MARKET, 2024–2031 46
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2026 46
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER BIOMARKERS MARKET 47
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN CANCER BIOMARKERS MARKET, 2025 48
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49
FIGURE 9 RISING PREVALENCE OF CANCER TO DRIVE MARKET 50
FIGURE 10 OMICS TECHNOLOGIES SEGMENT TO DOMINATE MARKET DURING
FORECAST PERIOD 51
FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51
FIGURE 12 CONSUMABLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 13 DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST
SHARE DURING FORECAST PERIOD 53
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53
FIGURE 16 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 55
FIGURE 17 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 72
FIGURE 18 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 78
FIGURE 19 CANCER BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 79
FIGURE 20 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 21 CANCER BIOMARKERS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 85
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN CANCER BIOMARKERS MARKET 86
FIGURE 23 PATENT ANALYSIS FOR CANCER BIOMARKERS, JANUARY 2016–DECEMBER 2025 95
FIGURE 24 MARKET POTENTIAL OF AI IN CANCER BIOMARKERS MARKET 98
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 100
FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT 101
FIGURE 27 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT 245
FIGURE 28 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT 305
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET,
2023–2025 (USD MILLION) 371
FIGURE 30 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, 2025 372
FIGURE 31 US: CANCER BIOMARKER MARKET SHARE ANALYSIS, 2025 374
FIGURE 32 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 376
FIGURE 33 CANCER BIOMARKERS MARKET: COMPANY FOOTPRINT, 2025 377
FIGURE 34 CANCER BIOMARKER MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 381
FIGURE 35 EV/EBITDA OF KEY VENDORS, 2026 383
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS, 2026 384
FIGURE 37 CANCER BIOMARKER MARKET: BRAND/PRODUCT COMPARISON
FOR CANCER BIOMARKER 384
FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 388
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT, 2025 394
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT, 2025 399
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2025 405
FIGURE 42 QIAGEN: COMPANY SNAPSHOT, 2025 411
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT, 2025 416
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 419
FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025 422
FIGURE 46 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 425
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT, 2025 427
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025 430
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025 433
FIGURE 50 RESEARCH DESIGN 449
FIGURE 51 KEY DATA FROM SECONDARY SOURCES 451
FIGURE 52 LIST OF PRIMARY SOURCES 452
FIGURE 53 KEY INDUSTRY INSIGHTS 453
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION,
AND REGION 454
FIGURE 55 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 455
FIGURE 56 CAGR PROJECTIONS 456
FIGURE 57 TOP-DOWN APPROACH 457
FIGURE 58 DATA TRIANGULATION 458
FIGURE 59 PARAMETRIC ASSUMPTIONS 459

---

---